Shaobo Chen
Research Subjects
Research Interests
Shaobo Chen has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Wei Cai
Department of Prevention and Therapy of Cardiovascular Diseases in Alpine Environment of Plateau, Characteristic Medical Center of PAP
3 shared publicationsXin Zhang
Department of Prevention and Therapy of Cardiovascular Diseases in Alpine Environment of Plateau, Characteristic Medical Center of PAP
2 shared publicationsBinsu Wang
Department of Cardiovascular Surgery ICU, General Hospital of Western Theater Command, Chengdu, 610000, China
1 shared publicationChao Liu
Department of Prevention and Therapy of Cardiovascular Diseases in Alpine Environment of Plateau, Characteristic Medical Center of PAP
1 shared publicationFang Hao
Department of Prevention and Therapy of Cardiovascular Diseases in Alpine Environment of Plateau, Characteristic Medical Center of PAP
1 shared publicationGuo-Hong Yang
Department of Prevention and Therapy of Cardiovascular Diseases in Alpine Environment of Plateau, Characteristic Medical Center of PAP
1 shared publication
Latest Publications
- Open Access
- 30 January 2026
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 12, 1701938
Identification and functional analysis of differential miRNAs in young and middle-aged adults with essential hypertension: exploring potential biomarkers and therapeutic targets
Background: Essential hypertension (EH) in young and middle-aged adults is a major risk factor for cardiovascular morbidity, yet the detailed molecular mechanisms underlying this condition have not been fully understood. MicroRNAs (miRNAs) have emerged as critical regulators of gene expression and have been increasingly associated with hypertension pathogenesis. Methods: Initially, high-throughput sequencing was employed to identify miRNAs with differential expression profiles in plasma collected from six EH patients compared with six matched healthy individuals. These candidate miRNAs were then confirmed through quantitative real-time PCR (qRT-PCR). Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were conducted to elucidate the potential biological roles of these miRNAs. Mendelian randomization (MR) was subsequently applied to investigate causal associations between EH and proteins targeted by the identified miRNAs. Results: Differential expression analysis revealed 14 upregulated miRNAs and 1 downregulated miRNA in the EH group. Following this, miRNAs were enriched through MiEAA, resulting in the selection of one downregulated miRNA and four upregulated miRNAs, which were subsequently validated by qRT-PCR. KEGG pathway analysis showed that genes regulated by upregulated miRNAs were significantly enriched in pathways related to hypoxia (HIF-1 signaling pathway), inflammation (MAPK and JAK-STAT signaling pathways), vascular remodeling (Focal adhesion and TGF-beta signaling pathways), and apoptosis (p53 signaling pathway). MR analysis identified GPCPD1, regulated by hsa-miR-10b-5p, as a significant risk factor for EH (OR = 1.04, 95% CI: 1.00–1.09, p = 2.32 × 10 −3 ). Moreover, proteins regulated by upregulated miRNAs, such as CDKN1B, PDGFRA, and THBS2, were found to be protective factors against EH. Conclusion: GPCPD1, regulated by hsa-miR-10b-5p, is a potential risk factor for EH, while CDKN1B, PDGFRA, and THBS2, regulated by upregulated miRNAs, may act as protective factors. These findings suggest new biomarkers and therapeutic targets for hypertension.
- 30 January 2026
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 12, 1701938
Open AccessIdentification and functional analysis of differential miRNAs in young and middle-aged adults with essential hypertension: exploring potential biomarkers and therapeutic targets
Background: Essential hypertension (EH) in young and middle-aged adults is a major risk factor for cardiovascular morbidity, yet the detailed molecular mechanisms underlying this condition have not been fully understood. MicroRNAs (miRNAs) have emerged as critical regulators of gene expression and have been increasingly associated with hypertension pathogenesis. Methods: Initially, high-throughput sequencing was employed to identify miRNAs with differential expression profiles in plasma collected from six EH patients compared with six matched healthy individuals. These candidate miRNAs were then confirmed through quantitative real-time PCR (qRT-PCR). Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were conducted to elucidate the potential biological roles of these miRNAs. Mendelian randomization (MR) was subsequently applied to investigate causal associations between EH and proteins targeted by the identified miRNAs. Results: Differential expression analysis revealed 14 upregulated miRNAs and 1 downregulated miRNA in the EH group. Following this, miRNAs were enriched through MiEAA, resulting in the selection of one downregulated miRNA and four upregulated miRNAs, which were subsequently validated by qRT-PCR. KEGG pathway analysis showed that genes regulated by upregulated miRNAs were significantly enriched in pathways related to hypoxia (HIF-1 signaling pathway), inflammation (MAPK and JAK-STAT signaling pathways), vascular remodeling (Focal adhesion and TGF-beta signaling pathways), and apoptosis (p53 signaling pathway). MR analysis identified GPCPD1, regulated by hsa-miR-10b-5p, as a significant risk factor for EH (OR = 1.04, 95% CI: 1.00–1.09, p = 2.32 × 10 −3 ). Moreover, proteins regulated by upregulated miRNAs, such as CDKN1B, PDGFRA, and THBS2, were found to be protective factors against EH. Conclusion: GPCPD1, regulated by hsa-miR-10b-5p, is a potential risk factor for EH, while CDKN1B, PDGFRA, and THBS2, regulated by upregulated miRNAs, may act as protective factors. These findings suggest new biomarkers and therapeutic targets for hypertension.
- 20 July 2020
- Published by Wiley in Clinical and Experimental Pharmacology and Physiology
- Vol. 47 (12) , 1953-1964
ELABELA improves endothelial cell function via the ELA–APJ axis by activating the PI3K/Akt signalling pathway in HUVECs and EA.hy926 cells
Destruction of endothelial cells (ECs) function is involved in the structural and functional pathophysiological processes of preeclampsia (PE). Vascular endothelial injury may pre‐exist for several years in women that develop PE and may pose increased risks for hypertension, coronary artery disease, and type‐2 diabetes mellitus. Previous findings showed that Elabela (ELA), the endogenous ligand of the apelin (APJ) receptor expressed mainly on ECs, may play a protective role in early pregnancy and prevent PE. However, the exact functional role and molecular mechanisms of ELA are unclear. Here, we aimed to classify whether and how ELA improves EC function via the ELA–APJ axis. Two human umbilical vein endothelial cell (HUVEC) lines, namely HUVECs and EA.hy926, were treated with ELA, and then their cellular activities were studied by performing CCK‐8 tests, scratch‐wound analysis, and tube‐formation assays. Doses of ELA exceeding 0.01 μmol/L markedly improved the cell viability, migration, and tube formation ability of HUVECs and EA.hy926 cells. Western blot analysis indicated that the above effects caused by ELA were related to upregulation of the APJ receptor and activation of PI3K/Akt signalling. Further verification tests were performed using the PI3K inhibitor wortmannin, and the results illustrated that inhibiting PI3K/Akt signalling blocked the positive effects of ELA on EC function and APJ receptor expression. Taken together, our findings indicate that ELA may alter EC function via the ELA–APJ axis and PI3K/Akt signalling and that ELA shows promise for use in endothelial dysfunction therapy for preventing and treating PE.
- 20 July 2020
- Published by Wiley in Clinical and Experimental Pharmacology and Physiology
- Vol. 47 (12) , 1953-1964
ELABELA improves endothelial cell function via the ELA–APJ axis by activating the PI3K/Akt signalling pathway in HUVECs and EA.hy926 cells
Destruction of endothelial cells (ECs) function is involved in the structural and functional pathophysiological processes of preeclampsia (PE). Vascular endothelial injury may pre‐exist for several years in women that develop PE and may pose increased risks for hypertension, coronary artery disease, and type‐2 diabetes mellitus. Previous findings showed that Elabela (ELA), the endogenous ligand of the apelin (APJ) receptor expressed mainly on ECs, may play a protective role in early pregnancy and prevent PE. However, the exact functional role and molecular mechanisms of ELA are unclear. Here, we aimed to classify whether and how ELA improves EC function via the ELA–APJ axis. Two human umbilical vein endothelial cell (HUVEC) lines, namely HUVECs and EA.hy926, were treated with ELA, and then their cellular activities were studied by performing CCK‐8 tests, scratch‐wound analysis, and tube‐formation assays. Doses of ELA exceeding 0.01 μmol/L markedly improved the cell viability, migration, and tube formation ability of HUVECs and EA.hy926 cells. Western blot analysis indicated that the above effects caused by ELA were related to upregulation of the APJ receptor and activation of PI3K/Akt signalling. Further verification tests were performed using the PI3K inhibitor wortmannin, and the results illustrated that inhibiting PI3K/Akt signalling blocked the positive effects of ELA on EC function and APJ receptor expression. Taken together, our findings indicate that ELA may alter EC function via the ELA–APJ axis and PI3K/Akt signalling and that ELA shows promise for use in endothelial dysfunction therapy for preventing and treating PE.